3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Advanced Cancer
3
Uveal Melanoma
2
Recurrence
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Various Advanced Cancer
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
durvalumab
7
Carboplatin
7
Docetaxel
6
Paclitaxel
5
Nivolumab
5
talazoparib
4
linifanib
4
Cisplatin
4
trifluridine tipiracil drug combination
3
tremelimumab
3
tislelizumab
3
depatuxizumab
3
ST 1481
3
S 1 (combination)
3
Panobinostat
3
Gemcitabine
3
zimberelimab
2
toripalimab
2
olaparib
2
motesanib diphosphate
2
mogamulizumab
2
TAS-114
2
Sorafenib
2
Rifampin
2
PM 01183
2
Oxaliplatin
2
MLN 8237
2
Itraconazole
2
Injections
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Solid Tumors
×
relatlimab
×
Clear all
NCT05498480
2024-02-20
RELATIVITY-111
Bristol-Myers Squibb
Phase 1
Completed
6 enrolled